TriangleBendamustine Hydrochloride (NCT04587687)
Bendamustine Hydrochloride trial for Recurrent Follicular Lymphoma (NCT04587687). This is a short film with English narration. The transcript is on this page, and the written brief is separate.
What the film says
Read the transcript
This trial is for adults with relapsed or refractory grade one, two, or three-A follicular lymphoma after prior treatment. CD30 staining must exceed one percent in tumor cells or surrounding tissue.
The idea: brentuximab vedotin carries a cell-division-blocking payload to CD30-bearing cells. Patients receive intravenous brentuximab with bendamustine for six three-week cycles. Responders without excessive toxicity may continue brentuximab alone for up to ten more cycles. Researchers assess complete response, overall response, and safety.
This phase 2 study plans 23 patients. Joseph Tuscano leads at UC Davis, Sacramento, the sole recruiting US site.
Public record; not medical advice.
Already in a trial?
It turns into a project to manage: visits, scans, labs, side effects and paperwork. Triangle keeps it organized in one place for you or for whoever's helping.
Organize my trial7-day free trial, then $9 a month. Cancel anytime.